Clinical Trial

Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD

Study acronym: PASSAGE
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 29, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.
Protocol Amendment History 4 changes
critical Enrollment closed, study ongoing 2026-07-30
notable Sponsor changed: Suzanne "Sue" Sisley MD -> Scottsdale Research Institute 2026-07-30
notable Primary completion pushed: 2026-03 -> 2026-07-30 2026-07-30
minor Completion pushed: 2026-03 -> 2026-10-01 2026-07-30
Trial Details
NCT Number NCT07275970
Lead Sponsor Scottsdale Research Institute
Conditions PTSD
Enrollment 24 participants
Start Date 2026-03-20
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29